BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Biosimilars
Artificial intelligence
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Thursday, March 28, 2024
See today's BioWorld
Home
» Astrazeneca tags EGFR T790M lung cancer mutation with Tagrisso nod
X
Upgrade your daily dose of biopharma and medtech news
Subscribe to BioWorld™ news services
See subscription options
To read the full story,
subscribe
or
sign in
.
Astrazeneca tags EGFR T790M lung cancer mutation with Tagrisso nod
Nov. 16, 2015
By
Marie Powers
No Comments
Astrazeneca plc moved AZD9291 (osimertinib) across the finish line in rapid fashion, gaining accelerated approval from the FDA a little more than 30 months after advancing the drug into the clinic in March 2013.
BioWorld